stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
48.95
1.60
+3.38%
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Shares outstanding
Septerna, Inc.'s shares outstanding at the end of fiscal 2025 was $44.3M, up 347.5% from $9.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $45.0M. Septerna, Inc. ranks 311th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $44.3M | 347.46% |
| FY2024 | $9.9M | 354.34% |
| FY2023 | $2.2M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $45.0M | 0.63% |
| Mar 2026 | $44.8M | 1.13% |
| Dec 2025 | $44.3M | (2.95%) |
| Sep 2025 | $45.6M | 3.25% |
| 7 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| ZYME Zymeworks Inc. compare | $73.0M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| SEPN Septerna, Inc. | $45.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- The full statement